Avolynt To Present at AASLD’s The Liver Meeting 2016

RESEARCH TRIANGLE PARK, N.C., November 9, 2016 – Avolynt, Inc. (“Avolynt”), a privately held biotech company focused on the development of therapeutics for metabolic diseases, announced today that it will present at The Liver Meeting® 2016 held by the American Association for the Study of Liver Diseases (AASLD), taking place November 11-15, 2016, at the John B. Haynes Veterans Memorial Convention Center in Boston.

Avolynt Chief Scientific Officer, William Wilkison, Ph.D. will present the poster titled, “Remogliflozin Etabonate Reduces FIB-4 and NAFLD Fibrosis Scores in Type 2 Diabetic Subjects” on Saturday November 12, 2016 during the session titled “Steatohepatitis: Clinical and Therapeutic.” The poster will provide an overview of clinical data supporting remogliflozin-etabonate, the company’s novel SGLT2 inhibitor being developed for nonalcoholic steatohepatitis (NASH).

NASH is a chronic disease that affects a growing patient population that is increasing in parallel with increased rates of obesity and diabetes. NASH is a hepatic manifestation of increased triglyceride accumulation in the liver leading to inflammation, fibrosis, cirrhosis and liver failure. NASH ranks as one of the major causes of Liver Transplant in United States and Europe, after hepatitis C. There are currently no approved therapeutics for the treatment of NASH.

About Remogliflozin Etabonate
Remogliflozin etabonate is a selective SGLT2 inhibitor and potent anti-oxidant in clinical development for NASH and type 2 diabetes. Remogliflozin has been dosed in over 800 patients in greater than twenty clinical trials. Remogliflozin has demonstrated statistically significant reductions in HbA1c with few adverse events. Low incidence rates of genitourinary infections and no increases in LDL-c, common side effects commonly associated with SGLT2 inhibitors, as well as reductions in both systolic and diastolic blood pressure have also been observed. Remogliflozin has demonstrated strong improvements in both insulin sensitivity and beta cell function as well as reductions in liver enzymes and oxidative stress.

About Avolynt, Inc.
Avolynt is a privately owned drug development company based in Research Triangle Park, North Carolina. Avolynt’s mission is to improve the lives of patients suffering from dysfunctions related to human metabolism. The Avolynt team has significant discovery and development experience across the metabolic syndrome, including diabetes, obesity, and nonalcoholic steatohepatitis (NASH). The Company is developing a novel SGLT2 inhibitor for the treatment of NASH and type 2 diabetes. Avolynt, through its wholly owned subsidiary BHV Pharma, holds an exclusive license to remogliflozin-etabonate for the global territory outside of Japan, Korea, and Taiwan. For more information about Avolynt, visit www.avolynt.com.

CONTACT:
+1 (919)659-5677
info@avolynt.com